Sildenafil for Treatment of Choroidal Ischemia
- Conditions
- Vitelliform Macular DystrophyAge-related Macular DegenerationRetinitis PigmentosaCentral Serous RetinopathyChoroidal Ischemia
- Interventions
- Other: Standard of Care SildenafilDrug: SildenafilDiagnostic Test: Ocular Coherence Tomography-Angiography (OCT-A)Other: Visual Acuity (VA)
- Registration Number
- NCT04356716
- Lead Sponsor
- Columbia University
- Brief Summary
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
- Detailed Description
Age-Related Macular Degeneration (AMD) is a sight-threatening visual disturbance that affects the macula in older ages. It is irreversible if the pigment epithelium is lost (dry AMD), but wet AMD can be arrested or delayed with the use of intraocular injections of one of 3 different compounds. All three drugs are injected into the eye in minute doses of usually 0.1 ml. These are usually injected at 4 to 6 week intervals and treatment may be extended for several years. Different patterns of injection times are followed but usually are monthly for 12 or more months, or monthly for 3 months and then extended observation at one to two month intervals unless vision (visual acuity) declines or Optical Coherence Tomography-angiography (OCT-A) shows recurrence of fluid or increase in size or amount of drusen (deposits of lipofuscin) in the retina. Vitelliform macular degeneration is a disorder that causes visual loss due to drusen in the macula, which have been shown to be identical to the deposits seen in macular degeneration. The goal of therapy in this proposal is to use sildenafil to increase choroidal blood flow to treat dry AMD and slow the progression of visual loss in vitelliform and age-related dry AMD as well as other macular, retinal and choroidal degenerations and dystrophies, as well as reduce or eliminate the number of injections required by slowing down transformation of dry AMD to wet AMD in treated patients.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 25
- Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy)
- Diagnosis of heart disease requiring use of nitrates
- Inability to be examined monthly or bi-monthly
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sildenafil Ocular Coherence Tomography-Angiography (OCT-A) Participants are prescribed sildenafil 40-80 mg daily. Sildenafil Visual Acuity (VA) Participants are prescribed sildenafil 40-80 mg daily. Standard of Care Sildenafil Standard of Care Sildenafil Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease. Sildenafil Sildenafil Participants are prescribed sildenafil 40-80 mg daily.
- Primary Outcome Measures
Name Time Method Change in Choroidal Perfusion Up to 5 Years Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Columbia University Medical Center, Edward Harkness Eye Institute
πΊπΈNew York, New York, United States